CYTH Stock Overview
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases.
Cyclo Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.20|
|52 Week High||US$10.40|
|52 Week Low||US$1.88|
|1 Month Change||2.33%|
|3 Month Change||-30.60%|
|1 Year Change||-78.50%|
|3 Year Change||-94.36%|
|5 Year Change||-95.18%|
|Change since IPO||-98.90%|
Recent News & Updates
|CYTH||US Biotechs||US Market|
Return vs Industry: CYTH underperformed the US Biotechs industry which returned -26.1% over the past year.
Return vs Market: CYTH underperformed the US Market which returned -20.4% over the past year.
|CYTH Average Weekly Movement||9.4%|
|Biotechs Industry Average Movement||13.1%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: CYTH is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: CYTH's weekly volatility (9%) has been stable over the past year.
About the Company
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer’s disease.
Cyclo Therapeutics Fundamentals Summary
|CYTH fundamental statistics|
Is CYTH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CYTH income statement (TTM)|
|Cost of Revenue||US$151.31k|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.55|
|Net Profit Margin||-915.39%|
How did CYTH perform over the long term?See historical performance and comparison
Is CYTH undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CYTH?
Other financial metrics that can be useful for relative valuation.
|What is CYTH's n/a Ratio?|
Price to Sales Ratio vs Peers
How does CYTH's PS Ratio compare to its peers?
|CYTH PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
APVO Aptevo Therapeutics
IKT Inhibikase Therapeutics
SONN Sonnet BioTherapeutics Holdings
YMTX Yumanity Therapeutics
CYTH Cyclo Therapeutics
Price-To-Sales vs Peers: CYTH is expensive based on its Price-To-Sales Ratio (13x) compared to the peer average (9.7x).
Price to Earnings Ratio vs Industry
How does CYTH's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: CYTH is good value based on its Price-To-Sales Ratio (13x) compared to the US Biotechs industry average (13.4x)
Price to Sales Ratio vs Fair Ratio
What is CYTH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||13x|
|Fair PS Ratio||13.2x|
Price-To-Sales vs Fair Ratio: CYTH is good value based on its Price-To-Sales Ratio (13x) compared to the estimated Fair Price-To-Sales Ratio (13.2x).
Share Price vs Fair Value
What is the Fair Price of CYTH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate CYTH's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CYTH's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CYTH's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Cyclo Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CYTH is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CYTH is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CYTH is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CYTH's revenue (67.2% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: CYTH's revenue (67.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CYTH's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Cyclo Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CYTH is currently unprofitable.
Growing Profit Margin: CYTH is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CYTH is unprofitable, and losses have increased over the past 5 years at a rate of 29.7% per year.
Accelerating Growth: Unable to compare CYTH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CYTH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: CYTH has a negative Return on Equity (-99.8%), as it is currently unprofitable.
Discover strong past performing companies
How is Cyclo Therapeutics's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: CYTH's short term assets ($15.9M) exceed its short term liabilities ($2.9M).
Long Term Liabilities: CYTH has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: CYTH is debt free.
Reducing Debt: CYTH had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CYTH has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: CYTH has less than a year of cash runway if free cash flow continues to reduce at historical rates of 33.7% each year
Discover healthy companies
What is Cyclo Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CYTH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CYTH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CYTH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CYTH's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CYTH has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
N. Fine (64 yo)
Mr. N. Scott Fine has been Chief Executive Officer of Cyclo Therapeutics, Inc. (formerly known as CTD Holdings, Inc.) since September 14, 2015. Mr. Fine served as the Chairman of Cyclo Therapeutics, Inc. s...
CEO Compensation Analysis
Compensation vs Market: N.'s total compensation ($USD1.08M) is above average for companies of similar size in the US market ($USD759.63K).
Compensation vs Earnings: N.'s compensation has increased whilst the company is unprofitable.
Experienced Management: CYTH's management team is seasoned and experienced (6.8 years average tenure).
Experienced Board: CYTH's board of directors are considered experienced (7.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CYTH insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 32.4%.
Cyclo Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Cyclo Therapeutics, Inc.
- Ticker: CYTH
- Exchange: NasdaqCM
- Founded: 1990
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$18.516m
- Shares outstanding: 8.42m
- Website: https://www.cyclotherapeutics.com
Number of Employees
- Cyclo Therapeutics, Inc.
- 6714 NW 16th Street
- Suite B
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/29 00:00|
|End of Day Share Price||2022/06/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.